EUVIMEDEUVIMED entdecken
Validierungsstudie

Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma

Aref L Zayed, Jomana Al Hroot, Ruba S Darweesh, Nidal A Qinna, Aysheh M Alshekhhossin, Omar M Al Kilani

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04373-8 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Aref L Zayed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan. alzayed@…. Hauptthemen laut MEDLINE: Erlotinib Hydrochloride, Resveratrol, Protein Kinase Inhibitors, Stilbenes. Die Arbeit nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Resveratrol is a natural compound and commonly used dietary supplement, especially for its anticancer properties. However, there is a lack of pharmacokinetic (PK) studies investigating its interactions with anticancer drugs, including tyrosine kinase inhibitors (TKIs). This study aimed to investigate the effect of resveratrol on erlotinib pharmacokinetics, a TKI indicated for non-small-cell lung cancer (NSCLC). Another aim was to develop and validate a new high-performance liquid chromatography with fluorescence detection (HPLC-FLD) method as a simple and cost-effective assay to quantify erlotinib levels in rat plasma in vivo. METHODS: HPLC-FLD was used to develop and validate a method for quantifying erlotinib in rat plasma. A PK study was conducted with four groups of male Sprague-Dawley rats: erlotinib (20 mg/kg) alone, erlotinib with either single or multiple doses of resveratrol (100 mg/kg), and a control group. Blood samples were collected and analyzed by HPLC-FLD, and the PK parameters were estimated. RESULTS: A 4-min runtime HPLC-FLD method was developed and validated. Single and multiple doses of resveratrol significantly increased the total area under the curve AUC 0 ∞ , by approximately 2- and 3-fold, respectively, while both decreased the clearance (Cl/F) of erlotinib by approximately 2-fold. CONCLUSION: Resveratrol, even at a single dose, can alter erlotinib pharmacokinetics which may cause clinically relevant drug interactions, particularly considering erlotinib significant interindividual variability and narrow therapeutic index. The new HPLC-FLD method is a reliable, simple, and cost-effective assay that can be used in erlotinib PK studies and therapeutic drug monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erlotinib HydrochlorideResveratrolProtein Kinase InhibitorsStilbenesAntineoplastic AgentsAnimalsMaleChromatography, High Pressure LiquidRats, Sprague-DawleyDrug InteractionsRatsReproducibility of ResultsFluorescence

Stichwörter der Autor:innen

Drug interactionErlotinibFluorescenceHPLCResveratrol

Substanzen

Erlotinib HydrochlorideResveratrolProtein Kinase InhibitorsStilbenesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan. alzayed@just.edu.jo.
  • Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 22110, Jordan.
  • University of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, Amman, 11196, Jordan.

Zitieren

APA

Zayed, A. L., Hroot, J. A., Darweesh, R. S., Qinna, N. A., Alshekhhossin, A. M., & Al Kilani, O. M. (2026). Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04373-8

Vancouver

Zayed AL, Hroot JA, Darweesh RS, Qinna NA, Alshekhhossin AM, Al Kilani OM. Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04373-8

BibTeX
@article{Zayed2026,
  author = {Zayed, Aref L and Hroot, Jomana Al and Darweesh, Ruba S and Qinna, Nidal A and Alshekhhossin, Aysheh M and Al Kilani, Omar M},
  title = {Resveratrol alters erlotinib pharmacokinetics in rats: application of a rapid HPLC-fluorescence method for quantifying erlotinib in plasma},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04373-8}
}
Kostenlos starten →